The pharmacy industry has set off a wave of listings, and corporate competition will intensify

In recent years, the "enclosure and race" in the capital market has become the main development goal of large retail pharmacies.
In order to achieve scale effects, major chain pharmacies are accelerating their expansion
.
It is worth noting that this is also leading to a new wave of drugstore listings
.
On November 25, Dajia Weikang made its first public offering and listed on the Growth Enterprise Market
.
The announcement shows that this time the proposed public offering of 51,626,425 shares, the issue price is 12.
37 yuan / share, and the total amount of funds raised is expected to be 638,618,900 yuan
.
According to public information, Dajia Weikang is a regional pharmaceutical distribution company, mainly engaged in the distribution and retail of pharmaceuticals, biological products, medical devices and other products, with business focused on Hunan
.
At present, the company has established a distribution network radiating the whole province of Hunan, basically covering hospitals above the third-level scale
.
Its annual revenue in 2020 is 2.
335 billion yuan, and the total number of retail specialty pharmacies has reached 115
.
With the exception of Dajia Weikang's listing on the ChiNext, the clarion call for IPO in the drugstore circle has actually sounded again in recent times
.
On October 15, Yuanxin Technology submitted a prospectus to the Hong Kong Stock Exchange
.
According to its prospectus, its annual revenue in 2020 will be 3.
629 billion yuan, and its subsidiary Yuanxin Pharmacy has opened 251 stores in 30 provinces in China
.
In August, SpeciHealth, which mainly sells specialty drugs for oncology and other critical diseases, formally submitted a prospectus to the Hong Kong Stock Exchange and plans to list on the main board
.
Statistics show that in 2020, Supai Health’s total revenue is 2.
7 billion yuan, and it has 81 specialty drug pharmacies in 29 provincial administrative regions across the country
.
It is reported that Supai Health has three main businesses, namely SMO (Clinical Trial Site Management Organization) business, PBM business, and PPS business
.
Among them, the specialty drug pharmacy business in the PBM business line has become the main source of income of Supai Health.
In other words, Supai's main income is "sell medicine" income
.
On June 23, Dingdang Health, a subsidiary of Dingdang Express, submitted a listing application to the Hong Kong Stock Exchange
.
According to the prospectus information, Dingdang Health's revenue in 2020 is 2.
229 billion yuan, and it has opened 302 offline smart pharmacies in 14 cities in China
.
In the same June, Sichuan Quanyuantang submitted a prospectus to the Hong Kong Stock Exchange, intending to list on the Hong Kong Main Board
.
At present, Quanyuantang’s annual revenue has reached 1.
249 billion yuan, and 369 offline pharmacies have been established in 13 cities in China
.
Judging from the above companies, this is undoubtedly a new wave of listings in the pharmaceutical retail circle.
Analysis believes that in the context of the continuous expansion of the retail pharmacy market and increasing competition, the future of the pharmaceutical retail industry will continue to emerge
.
With the continuous increase in the number of listed companies, the stable structure of the four private listed pharmacies, Dashenlin, Yixintang, Yifeng Pharmacy, and the common people may change, and intensify competition
.
In this context, the industry believes that the development of an enterprise should look at the long-term, not the immediate benefits
.
Therefore, while expanding the scale, relevant companies also need to consider developing other businesses to make up for the loss of net profit caused by the expansion of stores
.